Useful but concerning.
Devices already authorized for US sale can continue to be used and sold from existing inventory, and may continue receiving security updates until January 2027 under a separate FCC order issued ...
Nxera Pharma recently announced that its partner Neurocrine Biosciences received FDA IND acceptance for a Phase 2 trial of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results